PUBLISHER: The Business Research Company | PRODUCT CODE: 1948225
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948225
Smart insulin pens refer to insulin delivery devices designed to monitor and record dosage information, including volume, time, and type. Additionally, these devices may offer functionalities such as generating reports for sharing with healthcare professionals.
Two primary types of smart insulin pens exist first-generation pens and second-generation pens (equipped with Bluetooth or USB connectivity). Second-generation smart insulin pens incorporate Bluetooth or USB features to facilitate closer monitoring. These pens come in either prefilled or reusable forms and are utilized for the treatment of both type 1 diabetes and type 2 diabetes. Smart insulin pens find application across various end-users, including hospitals and clinics, ambulatory surgical centers, as well as home care settings.
Tariffs are impacting the smart insulin pens market by increasing costs of imported electronic sensors, microchips, batteries, and precision plastic components used in connected pen devices. Healthcare providers and patients in North America and Europe are most affected due to reliance on imported electronics, while Asia-Pacific faces higher manufacturing costs. These tariffs are increasing device prices and slowing adoption in cost-sensitive markets. However, they are also encouraging local device assembly, regional electronics sourcing, and innovation in cost-efficient smart insulin delivery solutions.
The smart insulin pens market research report is one of a series of new reports from The Business Research Company that provides smart insulin pens market statistics, including smart insulin pens industry global market size, regional shares, competitors with a smart insulin pens market share, detailed smart insulin pens market segments, market trends and opportunities, and any further data you may need to thrive in the smart insulin pens industry. This smart insulin pens market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The smart insulin pens market size has grown strongly in recent years. It will grow from $0.11 billion in 2025 to $0.12 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising prevalence of diabetes, increasing insulin-dependent patient population, growing awareness of dose accuracy, expansion of home healthcare solutions, availability of digital health platforms.
The smart insulin pens market size is expected to see strong growth in the next few years. It will grow to $0.16 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing integration with digital diabetes ecosystems, rising adoption of personalized insulin therapy, expansion of remote patient monitoring, growing focus on data-driven diabetes care, increasing investments in smart drug delivery technologies. Major trends in the forecast period include increasing adoption of connected insulin delivery devices, rising use of real-time dose tracking solutions, growing demand for home-based diabetes management, expansion of mobile app-integrated insulin pens, enhanced focus on patient adherence and safety.
The expanding global diabetic population is anticipated to accelerate the growth of the smart insulin pen market in the coming years. The diabetic population comprises individuals diagnosed with diabetes, a chronic metabolic disorder marked by persistently high blood glucose levels. The rise in diabetes prevalence is largely attributed to increasing obesity rates and sedentary lifestyles worldwide, which are key contributors to Type 2 diabetes. Smart insulin pens support improved diabetes care by enabling accurate insulin dose tracking, providing reminders, and integrating treatment data, thereby enhancing medication adherence and supporting better glycemic control. For example, in 2025, data from the International Diabetes Federation indicated that in 2024, approximately 589 million adults aged 20-79 were living with diabetes, with projections estimating this number to rise to 853 million by 2050, and more than four out of five adults with diabetes residing in low- and middle-income countries. As a result, the growing global burden of diabetes is fueling the adoption of smart insulin pens.
Leading companies in the smart insulin pen space are focusing on the development of integrated solutions that combine real-time glucose monitoring, automated dose calculations, and missed-dose detection to streamline insulin therapy and minimize the risk of hypoglycemia. These systems integrate Bluetooth-enabled insulin pens, mobile applications, and compact continuous glucose monitoring devices to deliver personalized dosing recommendations, identify dosing errors, and support improved glycemic outcomes. For instance, in December 2024, Medtronic, a United States-based medical technology company, introduced its Smart MDI System, which pairs a smart insulin pen with the Simplera continuous glucose monitor to provide real-time, individualized dosing guidance. The system uniquely offers missed-meal dose detection and corrective recommendations, enabling users to address skipped or incorrect injections. Real-world evidence showed that patients who consistently acted on these alerts achieved Time in Range levels of approximately 67-71%, highlighting the capability of such technologies to enhance glucose management.
In October 2023, Novo Nordisk A/S acquired Biocorp, a France-based medical device company specializing in the development and manufacturing of drug-delivery systems and medical devices, for $164.5 million. This acquisition is expected to enable Novo Nordisk to further invest in Biocorp's device development and expedite its ambitions within devices and delivery solutions.
Major companies operating in the smart insulin pens market are Companion Medical, Novo Nordisk A/S, F. Hoffmann-La Roche AG, Emperra GmbH E-Health Technologies, Diamesco Co. Ltd., Digital Medics Pvt Ltd., Bigfoot Biomedical, Diabnext, Insulet Corporation, Sanofi India, Becton Dickinson, Biocon Ltd, Johnson & Johnson, Terumo, NIPRO, Medtronic PLC, Ypsomed Holding AG, Patients Pending Ltd, Dexcom, Insujet, Eli Lilly, Abbott Laboratories, Tandem Diabetes Care Inc.
North America was the largest region in the smart insulin pens market in 2025. Western Europe was the second largest region in the global smart insulin pens market share. The regions covered in the smart insulin pens market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the smart insulin pens market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The smart insulins pens market consists of sales of instruments such as first-generation pens and second-generation pens (Bluetooth enabled, USB connected). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Smart Insulin Pens Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses smart insulin pens market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for smart insulin pens ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The smart insulin pens market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.